Risk analysis of musculoskeletal pain intervention using corticosteroid during COVID-19 pandemic : a cohort study
Background: Most international bodies recommended against musculoskeletal steroid injection during the COVID-19 pandemic, fearing that the immunosuppressive effects of the steroid could worsen COVID-19 infection, thus prolonging the suffering of patients with severe musculoskeletal disease. The authors' aim is to analyze the risk of COVID-19 infection after musculoskeletal injections.
Methods: This is a retrospective study of patients who visited a sports medicine clinic and received musculoskeletal steroid injections between January 1, 2020 and February 28, 2021. The collected data was compared with the national COVID-19 registry to identify positive COVID-19 patients. The patients were only considered positive for COVID-19 following corticosteroid injection within 3 months after injection.
Results: Out of 502 steroid injections; 79.7% (n = 400) received a single injection in one day, 19.1% (n = 96) received steroid injections at 2 sites in one day, and 1.2% (n = 6) received steroid injections at 3 sites in one day. Using the Fisher's exact test, there was no statistically significant association of COVID-19 infection between the steroid group and control group (relative risk, 1.44; 95% confidence interval, 0.9-23.1, P = 0.654). Only one patient contracted mild COVID-19 with no post COVID complications.
Conclusions: The authors recommend the use of musculoskeletal steroid injections in clinically indicated situation without having increased risk of COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:36 |
|---|---|
| Enthalten in: |
The Korean journal of pain - 36(2023), 1 vom: 01. Jan., Seite 106-112 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mohamad, Azwan Aziz [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Revised 12.01.2023 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3344/kjp.22249 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM350269343 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM350269343 | ||
| 003 | DE-627 | ||
| 005 | 20231226044627.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3344/kjp.22249 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1167.xml |
| 035 | |a (DE-627)NLM350269343 | ||
| 035 | |a (NLM)36514932 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mohamad, Azwan Aziz |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Risk analysis of musculoskeletal pain intervention using corticosteroid during COVID-19 pandemic |b a cohort study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 12.01.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Background: Most international bodies recommended against musculoskeletal steroid injection during the COVID-19 pandemic, fearing that the immunosuppressive effects of the steroid could worsen COVID-19 infection, thus prolonging the suffering of patients with severe musculoskeletal disease. The authors' aim is to analyze the risk of COVID-19 infection after musculoskeletal injections | ||
| 520 | |a Methods: This is a retrospective study of patients who visited a sports medicine clinic and received musculoskeletal steroid injections between January 1, 2020 and February 28, 2021. The collected data was compared with the national COVID-19 registry to identify positive COVID-19 patients. The patients were only considered positive for COVID-19 following corticosteroid injection within 3 months after injection | ||
| 520 | |a Results: Out of 502 steroid injections; 79.7% (n = 400) received a single injection in one day, 19.1% (n = 96) received steroid injections at 2 sites in one day, and 1.2% (n = 6) received steroid injections at 3 sites in one day. Using the Fisher's exact test, there was no statistically significant association of COVID-19 infection between the steroid group and control group (relative risk, 1.44; 95% confidence interval, 0.9-23.1, P = 0.654). Only one patient contracted mild COVID-19 with no post COVID complications | ||
| 520 | |a Conclusions: The authors recommend the use of musculoskeletal steroid injections in clinically indicated situation without having increased risk of COVID-19 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Injections | |
| 650 | 4 | |a Malaysia | |
| 650 | 4 | |a Musculoskeletal Pain | |
| 650 | 4 | |a Pain Management | |
| 650 | 4 | |a Pandemics | |
| 650 | 4 | |a Risk Factors | |
| 650 | 4 | |a Steroids. | |
| 700 | 1 | |a Mohamed, Nahar Azmi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Korean journal of pain |d 2010 |g 36(2023), 1 vom: 01. Jan., Seite 106-112 |w (DE-627)NLM198856288 |x 2005-9159 |7 nnns |
| 773 | 1 | 8 | |g volume:36 |g year:2023 |g number:1 |g day:01 |g month:01 |g pages:106-112 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3344/kjp.22249 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 36 |j 2023 |e 1 |b 01 |c 01 |h 106-112 | ||